Bio‐Inspired Albumin Platform for Synergistic Co‐Delivery of Tanespimycin, Dasatinib, and Quercetin and Enhanced Therapeutic Efficacy in Triple‐Negative Breast Cancer
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Anna Deręgowska und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biotechnology, Collegium Medicum, University of Rzeszow, Rzeszow, Poland. Hauptthemen laut MEDLINE: Quercetin, Benzoquinones, Triple Negative Breast Neoplasms, Dasatinib. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Despite increasing awareness of molecular subtypes of breast cancer, this heterogeneous malignant disease is still one of the leading causes of cancer death in women worldwide. Although receptor status may define the precise therapeutic targets, treatment of triple‐negative breast cancer (TNBC) relies mainly on chemotherapy with accompanying side‐effects. Thus, there is a need for the design and testing of more effective drug delivery systems and drug combinations. In this study, biomimetic self‐assembled bovine serum albumin (BSA) capsules (Cs) co‐loaded with a new drug combination, namely two drugs tanespimycin (T) and dasatinib (D), and natural compound quercetin (Q), were fabricated, and their anti‐breast cancer effects were assessed. (T‐D‐Q)‐BSA Cs were more active against TNBC cells compared to other types of breast cancer. Encapsulated drugs potentiated apoptotic cell death in TNBC cells compared to the effect of the free three‐drug formulation. In TNBC cells with mutated TP53 , (T‐D‐Q)‐BSA Cs also induced necroptotic cell death accompanied by RAP1‐mediated stimulation of NFκB activity and IL‐6‐related proinflammatory response. (T‐D‐Q)‐BSA Cs also inhibited TNBC‐based tumor growth in two zebrafish xenograft in vivo models. In conclusion, the efficacy of (T‐D‐Q)‐BSA Cs as a novel therapeutic strategy to eradicate TNBC in vitro and in vivo was demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Biotechnology, Collegium Medicum, University of Rzeszow, Rzeszow, Poland.
- Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
- Department of Medical Chemistry, Medical University of Lublin, Lublin, Poland.
- Faculty of Chemistry, University of Warsaw, Warsaw, Poland.
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
ORCID-Profile: Anna Deręgowska, Paulina Stec, Olga Kołodziej, Magdalena Słowik-Borowiec, Krzysztof Pawlik, Maciej Wnuk, Anna Lewińska
Zitieren
APA
Deręgowska, A., Oklejewicz, B., Stec, P., Wawruszak, A., Boguszewska-Czubara, A., Lichoń, Ł., Starzyk, J., Kołodziej, O., Słowik-Borowiec, M., Krogul-Sobczak, A., Gamian, A., Pawlik, K., Łodej, N., Wnuk, M., & Lewińska, A. (2026). Bio‐Inspired Albumin Platform for Synergistic Co‐Delivery of Tanespimycin, Dasatinib, and Quercetin and Enhanced Therapeutic Efficacy in Triple‐Negative Breast Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71690
Vancouver
Deręgowska A, Oklejewicz B, Stec P, Wawruszak A, Boguszewska-Czubara A, Lichoń Ł, et al. Bio‐Inspired Albumin Platform for Synergistic Co‐Delivery of Tanespimycin, Dasatinib, and Quercetin and Enhanced Therapeutic Efficacy in Triple‐Negative Breast Cancer. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71690
BibTeX
@article{Dergowska2026,
author = {Deręgowska, Anna and Oklejewicz, Bernadetta and Stec, Paulina and Wawruszak, Anna and Boguszewska-Czubara, Anna and Lichoń, Łukasz and Starzyk, Jakub and Kołodziej, Olga and Słowik-Borowiec, Magdalena and Krogul-Sobczak, Agnieszka and Gamian, Andrzej and Pawlik, Krzysztof and Łodej, Norbert and Wnuk, Maciej and Lewińska, Anna},
title = {Bio‐Inspired Albumin Platform for Synergistic Co‐Delivery of Tanespimycin, Dasatinib, and Quercetin and Enhanced Therapeutic Efficacy in Triple‐Negative Breast Cancer},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71690}
}
EUVIMED